Etanercept

Indications
 Subcutaneous
Ankylosing spondylitis
Adult: 25 mg twice wkly at intervals of 3-4 days. Discontinue treatment if no response after 3 mth.
Subcutaneous
Rheumatoid arthritis
Adult: 25 mg twice wkly at intervals of 3-4 days. Discontinue treatment if no response after 3 mth.
Subcutaneous
Juvenile idiopathic arthritis
Child: 2-17 yr: 0.4 mg/kg twice wkly at intervals of 3-4 days. Discontinue treatment if no response after 6 mth or initial response is not maintained. Max: 50 mg/wk.
Subcutaneous
Chronic moderate to severe plaque psoriasis
Adult: ≥18 yr: 50 mg twice wkly at intervals of 3-4 days, may be given for 12 wk, thereafter reduce to 25 mg twice wkly or 50 mg wkly. Continue treatment until remission is achieved, up to 24 wk. Discontinue if no response after 3 mth.
Contraindications
 Pregnancy, lactation, active severe chronic or localised infection and sepsis.
Warnings / Precautions
 History of recurrent infections or risk of infection. Patients with underlying conditions that may predispose them to infections. May reactivate hepatitis B virus when used in HBV carriers. May develop autoantibodies and SLE-like symptoms. Blood dyscrasias, lymphoma, CNS demyelinating disorders, cardiac disorders, elderly, children <4 yr.
Adverse Reactions
 Mild to moderate Inj site reactions, upper resp infections and sinusitis, discoid lupus and necrotising vasculitis, urticaria, rash, malignancy, GI upset, autoantibody formation. Rarely, blood dyscrasias, CNS demyelinating disorders, SLE and lupus-like syndrome.
Drug Interactions
 Avoid concomitant use of etanercept with interleukin-1 antagonist, live vaccines, cyclophosphamide, sulfasalazine or anakinra.
See Below for More etanercept Drug Interactions
Lab Interactions
 May interfere with troponin determinations.
Mechanism of Actions
 Etanercept is a recombinant soluble human tumor necrosis factor (TNF) that binds specifically to TNF receptors, thus blocking interaction of human TNF with endogenous cell-surface TNF receptors leading to an inhibition in the inflammatory processes of RA.
Onset: 2-3 wk.
Excretion: Elimination half-life: 72-132 hr (after SC admin).
ATC Classification
 L04AB01 - etanercept ; Belongs to the class of tumor necrosis factor alpha (TNF-a) inhibitors. Used as immunosuppressants.
Available As
  • Etanercept 25 mg
  • Etanercept 50 mg

    • Subscribe for latest updates

    Subscribe to our e-mail newsletter to receive updates.

    No comments yet.

    Post Review about Etanercept


    Etanercept Containing Brands

    We are Developing Our database, More results coming soon.

    Etanercept is used in following diseases

    We are Developing Our database, More results coming soon.

    Drug - Drug Interactions of Etanercept

    We are Developing Our database, More results coming soon.